Home
About Us
Company Profile
Enterprise Honor
Enterprise Qualification
Corporate Shareholder
Science & Innovation
Molecular Glue
GLUETAC
Degrader-Antibody Conjugates
Journal Articles
Pipeline
GT919
GT929
GT818
GT820
Partnerships
Local Cooperation
Out Licensing
Global Cooperation
University Cooperation
Subject Recruitment
Multiple myeloma
Non-Hodgkin’s lymphoma
Talent Strategy
Talent concept
Employee honor
Employee Showcase
Welfare system
Job Openings
Talent scheme
Press Releases
R&D advancements
Technology Platform
Media Coverage
Contact Us
China
USA
Canada
Home
About Us
Company Profile
Enterprise Honor
Enterprise Qualification
Corporate Shareholder
Science & Innovation
Molecular Glue
GLUETAC
Degrader-Antibody Conjugates
Journal Articles
Pipeline
GT919
GT929
GT818
GT820
Partnerships
Local Cooperation
Out Licensing
Global Cooperation
University Cooperation
Subject Recruitment
Multiple myeloma
Non-Hodgkin’s lymphoma
Talent Strategy
Talent concept
Employee honor
Employee Showcase
Welfare system
Job Openings
Talent scheme
Press Releases
R&D advancements
Technology Platform
Media Coverage
Contact Us
China
USA
Canada
中文
English
中文
English
The clinical trial application for GT919, the first molecular glue pipeline of Gluetacs Therapeutics, has been accepted.
